Saturday, 4 July 2026 edition — The Vital Record
Vol. 1 · No. 31
Saturday, 4 July 2026
“Primary sources first, readers always.”
In this edition
The Vital Record opens its first edition on a day defined by a landmark data-integrity reckoning: FDA's proposed withdrawal of avacopan follows an NEJM retraction documenting post-hoc endpoint manipulation in the drug's pivotal trial, while a Lancet-published Phase 3 demonstrates lutetium-177 radionuclide therapy extends progression-free survival by nearly ten months over everolimus in neuroendocrine tumours, and WHO's declaration of a Bundibugyo Ebola PHEIC marks international spread of a species with no approved vaccine or treatment.
Trials Today
Phase 3
COMPETE (NCT03049189)
— 177Lu-edotreotide vs everolimus in GEP NETs; 9.8-month PFS gain, HR 0.67; results published in Lancet
Phase 3
ORIGIN 3 — atacicept (NCT04716231)
— IgA nephropathy; PDUFA deadline July 7, 2026; 42% UPCR reduction vs placebo at week 36; NEJM published
Phase 2/3
Etrasimod Crohn's (NCT04173273)
— Pfizer program terminated; results posted to registry; S1P modulator class extension from UC to Crohn's foreclosed
Phase 3
TRONTIER 1 — trontinemab (NCT07169578)
— Roche bispecific anti-amyloid antibody with TfR1-mediated BBB transit; recruiting 800 participants; primary completion June 2028
Phase 3
LoTam (NCT06671912)
— Low-dose tamoxifen vs aromatase inhibitor in 1,556-patient breast cancer trial across 733 sites; SUSPENDED, no reason stated
Who's Who
Robert Michael
Chief Executive Officer, AbbVie
Announced AbbVie's $10.9 billion all-cash acquisition of Apogee Therapeutics on June 22, 2026, adding zumilokibart (APG777), an IL-13–targeting monoclonal antibody in late-stage development for atopic dermatitis and asthma, to AbbVie's immunology pipeline as it braces for Humira biosimilar headwinds.
The story →
The Daily Record
Medicine & biotech, fully cited, in your inbox each morning.
Free. Unsubscribe anytime.
← The archive